All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Immune Profile in Patients With COVID-19: Lymphocytes Exhaustion Markers in Relationship to Clinical Outcome

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F21%3AN0000067" target="_blank" >RIV/00064190:_____/21:N0000067 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/21:10428115

  • Result on the web

    <a href="http://dx.doi.org/10.3389/fcimb.2021.646688" target="_blank" >http://dx.doi.org/10.3389/fcimb.2021.646688</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3389/fcimb.2021.646688" target="_blank" >10.3389/fcimb.2021.646688</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Immune Profile in Patients With COVID-19: Lymphocytes Exhaustion Markers in Relationship to Clinical Outcome

  • Original language description

    The velocity of the COVID-19 pandemic spread and the variable severity of the disease course has forced scientists to search for potential predictors of the disease outcome. We examined various immune parameters including the markers of immune cells exhaustion and activation in 21 patients with COVID-19 disease hospitalised in our hospital during the first wave of the COVID-19 pandemic in Slovakia. The results showed significant progressive lymphopenia and depletion of lymphocyte subsets (CD3(+), CD4(+), CD8(+) and CD19(+)) in correlation to the disease severity. Clinical recovery was associated with significant increase in CD3(+) and CD3(+)CD4(+) T-cells. Most of our patients had eosinopenia on admission, although no significant differences were seen among groups with different disease severity. Non-survivors, when compared to survivors, had significantly increased expression of PD-1 on CD4(+) and CD8(+) cells, but no significant difference in Tim-3 expression was observed, what suggests possible reversibility of immune paralysis in the most severe group of patients. During recovery, the expression of Tim-3 on both CD3(+)CD4(+) and CD3(+)CD8(+) cells significantly decreased. Moreover, patients with fatal outcome had significantly higher proportion of CD38(+)CD8(+) cells and lower proportion of CD38(+)HLA-DR(+)CD8(+) cells on admission. Clinical recovery was associated with significant decrease of proportion of CD38(+)CD8(+) cells. The highest AUC values within univariate and multivariate logistic regression were achieved for expression of CD38 on CD8(+) cells and expression of PD1 on CD4(+) cells alone or combined, what suggests, that these parameters could be used as potential biomarkers of poor outcome. The assessment of immune markers could help in predicting outcome and disease severity in COVID-19 patients. Our observations suggest, that apart from the degree of depletion of total lymphocytes and lymphocytes subsets, increased expression of CD38 on CD3(+)CD8(+) cells alone or combined with increased expression of PD-1 on CD3(+)CD4(+) cells, should be regarded as a risk factor of an unfavourable outcome in COVID-19 patients. Increased expression of PD-1 in the absence of an increased expression of Tim-3 on CD3(+)CD4(+) and CD3(+)CD8(+) cells suggests potential reversibility of ongoing immune paralysis in patients with the most severe course of COVID-19.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30102 - Immunology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY

  • ISSN

    2235-2988

  • e-ISSN

  • Volume of the periodical

    11

  • Issue of the periodical within the volume

    15.4.2021

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    15

  • Pages from-to

    Article Number 646688

  • UT code for WoS article

    000645107300001

  • EID of the result in the Scopus database

    2-s2.0-85104994216